Upadacitinib (Rinvoq)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses upadacitinib (Rinvoq) 15-mg extended-release oral tablets Indication: For the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other DMARDs; Rinvoq (upadacitinib) may be used as monotherapy or in combination with methotrexate